Keating Financial Advisory Services’s Trevi Therapeutics TRVI Stock Holding History
Bought
Maintained
Sold
Other funds holding TRVI
Keating Financial Advisory Services's TRVI Position: Q3 2026 in Review
Keating Financial Advisory Services held its Trevi Therapeutics (TRVI) position steady in Q3 2026 at 2 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #2548.
Keating Financial Advisory Services first reported a position in TRVI in Q1 2026 and has held it in 3 quarters since. The position peaked at $37 in Q2 2026. 223 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.
- Keating Financial Advisory Services held 2 shares of Trevi Therapeutics worth $29 as of Q3 2026.
- Keating Financial Advisory Services left its Trevi Therapeutics share count unchanged in Q3 2026.
- Trevi Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q3 2026, its #2548 holding.
- Keating Financial Advisory Services first reported a position in Trevi Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Keating Financial Advisory Services's Trevi Therapeutics position peaked at $37 in Q2 2026.
- 223 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.
Based on Keating Financial Advisory Services's 13F filing for Q3 2026, filed 12 Nov 2026.